Separation and Characterization of Two Fibrinolytic Inhibitors from Human Placenta

M Uszynski; U Abildgaard

doi:10.1055/s-0038-1654331

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1971; 25(03): 580-589
DOI: 10.1055/s-0038-1654331

Originalarbeiten – Original Articles – Travaux Originaux

Schattauer GmbH

Separation and Characterization of Two Fibrinolytic Inhibitors from Human Placenta

Authors

M Uszynski

¹Haematological Research Laboratory, Dept. IX, Ullevål Hospital, Oslo, Norway

²First Dept. of Obstetrics and Gynaecology, Medical School of Bialystok, Poland
U Abildgaard

¹Haematological Research Laboratory, Dept. IX, Ullevål Hospital, Oslo, Norway

²First Dept. of Obstetrics and Gynaecology, Medical School of Bialystok, Poland

Abstract

Summary

Procedures for the separation of two inhibitors of the activation of plasminogen to plasmin by urokinase are described. Tissue thromboplastin was removed by adsorption to Al(0H)₃ gel followed by ultracentrifugation. Plasminogen, plasminogen activator, a coagulation inhibitor and hemoglobin were removed by ion exchange chromatography (CM- or DEAE-Sephadex with NaCl gradients). The minor UK inhibitor is a relative basic protein with a pI of about 5.8. The major inhibitor was purified further by isoelectric focusing, preparative electrophoresis in polyacrylamide gel, and gel filtration. This inhibitor has α₁-motility, the pI is about 5.2, and the molecular weight about 100,000. It inactivates urokinase progressively, but does not inhibit streptokinase, plasmin or thrombin.

Full Text

References

References
1 Abildgaard, UPurification of two progressive antithrombins of human plasma. Scand. J. clin. Invest 19: 190 1967;
2 Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand. J. clin. Lab. Invest 21: 89 1968;
3 Andrews P. Molecular-sieve chromatography. Brit. med. Bull 22: 109 1966;
4 Berg W, Korsan-Bengtsen K, Ygge I. Human and bovine plasminogenfree thrombin, purified by means of gel filtration and ion exchange chromatography. Thrombos. Diathes. haemorrh. (Stuttg) 15: 501 1966;
5 Berg W, Korsan-Bengtsen K, Ygge I. Preparation of human plasminogen suitable as substrate for quantitative determination of plasminogen activators. Thrombos. Diathes. haemorrh. (Stuttg) 15: 501 1966; b
6 Bergstrom K, Wallen P. Removal of contaminating plasminogen from purified bovine fibrinogen. ArkivKemi 17: 503 1961;
7 Brahman P, Astrup T. Selective inhibition in human pregnancy blood of urokinase induced fibrinolysis. Scand. J. clin. Lab. Invest 15: 603 1963;
8 Clarice N, O’Meara R. A. Q. Intracellular location of thromboplastic activity in the cells of human chorion. Brit. J. Haemat 12: 536 1966;
9 Davis B. J. Disc electrophoresis II. Method and application to human serum proteins. Ann. N.Y. Acad. Sei 121: 404 1964;
10 Goa J. A micro biuret method for protein determination. Scand. J. clin. Lab. Invest 05: 218 1953;
11 Hedner, Ulla Nilsson I. n. gaMarie, Jacobsen G. D. Demonstration of low content of fibrinolytic inhibitors in individuals with high fibrinolytic capacity. Scand. J. clin. Lab. Invest 04: 329 1970;
12 Helle I. The inhibitory effect of large concentrations of streptokinase as related to proteolytic activity and proactivator function of human euglobulin. Scand. J. Haemat 01: 240 1964;
13 Hjort P. F. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Thesis. Scand. J. clin. Lab. Invest. 9, Suppl. 27 1957
14 Januszo T, Buluk K, Uszynska-Folejewska R, Uszynski M. Measurement of the inhibitor of plasminogen activation in the euglobulin test. Pol. med. J 04: 914 1966;
15 Jovin T, Ghrambach A, Naughton M. A. An apparatus for preparative temperature- regulated polyacrylamide gel electrophoresis. Analyt. Biochem 09: 351 1964;
16 Kawano T, Morimoto K, TJemura Y. Urokinase inhibitor in human placenta. Nature (Lond) 217: 253 1968;
17 Kawano T, Morimoto K, Uemura Y. Partial purification and properties of urokinase inhibitor from human placenta. J. Biochem 03: 333 1970;
18 Loeb J. Le cofacteur plasmatique de l’heparine et ses rapports avec l’antithrombine. Arch. Sei. physiol 10: 129 1956;
19 Martin R. G, Ames B. N. A method for determining the sedimentation behavior of enzymes : Application to protein mixtures. J. biol. Chem 236: 1372 1961;
20 Paraskevas, Maria Nilsson IngaMarie, Martinsson Gunilla. A method for determining serum inhibitors of plasminogen activation. Scand. J. clin. Lab. Invest 14: 138 1962;
21 Permin P. M. The fibrinolytic activator in animal tissue. Acta physiol, scand 21: 159 1950;
22 Semar M, Skoza L, Johnson A. J. Partial purification and properties of a plasminogen activator from human erythrocytes. J. clin. Invest 10: 1777 1969;
23 Shaper A. G. Fibrinolytic activity in pregnancy, during parturition, and in the puerperium. Lancet II: 874 1966;
24 Todd A. S. Histological activation of fibrinolysin activator. J. Path. Bact 78: 281 1959;
25 Uszynski M, Uszynska-Folejewska R. Plasminogen activator and urokinase inhibitor in myometrium, placenta and amniotic fluid. Amer. J. Obstet. Gynec 07: 1041 1969;
26 Uszynski M, Abildgaard U. Purification and properties of two fibrinolytic inhibitors from human placenta. Int. Congr. Hemat., München 1970. Symposium antifibrinolytic substances, Addendum abstract sheet..
27 Uszynski M, Godal H. G. An inhibitor of factor VII from human placenta. Scand. J. Haemat. (In press.)
28 Vesterberg O, Svensson H. Isoelectric fractionation, analysis and characterization of ampholytes in natural pH gradients. IV. Further studies on the resolving power in connection with separation of myoglobin. Acta chem. scand 20: 820 1966;